Can the personalized medicine approach contribute in controlling tuberculosis in general and India in particular?

IF 5.1 4区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Precision Clinical Medicine Pub Date : 2020-06-04 DOI:10.1093/pcmedi/pbaa021

Nikhat Khan, Aparup Das

引用次数: 4

Abstract

Abstract Poor drug compliance and drug-resistant Mycobacterium tuberculosis are the two principal obstacles in controlling tuberculosis (TB) in endemic regions including India, which has contributed the most to global TB burden. We argue here that a personalized medicine approach, to start with the N-acetyl transferase-2–isoniazid (NAT2–INH) model, could be a step forward in dealing with both these limitations in controlling TB in India.

查看原文本刊更多论文

个体化医疗方法能否有助于控制结核病，特别是在印度?

药物依从性差和耐药结核分枝杆菌是包括印度在内的结核病流行地区控制结核病(TB)的两大主要障碍，印度是全球结核病负担最大的国家。我们在这里认为，从n -乙酰转移酶-2 -异烟肼(NAT2-INH)模型开始的个性化医疗方法可能是解决印度控制结核病的这两个限制的一个进步。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Precision Clinical Medicine MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

10.80

自引率

0.00%

发文量

审稿时长

5 weeks

期刊介绍： Precision Clinical Medicine (PCM) is an international, peer-reviewed, open access journal that provides timely publication of original research articles, case reports, reviews, editorials, and perspectives across the spectrum of precision medicine. The journal's mission is to deliver new theories, methods, and evidence that enhance disease diagnosis, treatment, prevention, and prognosis, thereby establishing a vital communication platform for clinicians and researchers that has the potential to transform medical practice. PCM encompasses all facets of precision medicine, which involves personalized approaches to diagnosis, treatment, and prevention, tailored to individual patients or patient subgroups based on their unique genetic, phenotypic, or psychosocial profiles. The clinical conditions addressed by the journal include a wide range of areas such as cancer, infectious diseases, inherited diseases, complex diseases, and rare diseases.